Enhanced Protection: Discover the 13% Boost with New Low-Dose mNEXSpike COVID Vaccine
The COVID-19 pandemic continues to challenge global health, prompting advancements in vaccine technology to combat the evolving virus. Moderna has introduced an innovative vaccine, mNEXSpike, which gained approval in 2025. This low-dose mRNA vaccine is tailored for individuals aged 65 and older, as well as high-risk groups between 12 and…
bubmagNovember 26, 2025